Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Montelukast for Relapse Prevention in Childhood Nephrotic Syndrome
NCT04818723Completed
- Sponsor
- Nishtar Medical University
- Start
- Feb 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of montelukast in Idiopathic nephrotic syndrome (INS) (2 arms), sponsored by Nishtar Medical University. Primary endpoint: Prevention of relapse in idiopathic childhood nephrotic syndrome at 1 year. Started Feb 2019; status: completed.
02
Drugs
montelukast
03
Conditions
Idiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on NCT04818723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04818723.